GSK has been found guilty of bringing discredit on the pharma industry after a complainan | GSK has been found guilty of ...

Thus far in the calendar year 2025, the stock price of GSK Pharma has zoomed 40 per cent, as against 1.8 per cent rise in BSE ...

GSK’s blood cancer drug Blenrep won regulatory approval in the U.K., marking the medicine’s return to the market after it was ...

April 15 (Reuters) - British pharmaceutical giant GSK (GSK.L), opens new tab has not met required ethical and regulatory standards in the marketing and prescription information for its Omjjara ...

GSK (NYSE:GSK) reported that a study showed its ... versus daratumumab in combination with bortezomib plus dexamethasone, or DVd, as a second line or later treatment for relapsed or refractory ...

Overall, GSK's established product line creates the enormous cash flows needed to fund the average $800 million in development costs per new drug. A powerful distribution network sets up the ...

GSK plc GSK announced that the FDA has approved its oral antibiotic gepotidacin for treating uncomplicated urinary tract infections (uUTIs) in female adults and adolescents. A commercial launch ...

GSK has secured the first regulatory approval for Blenrep since the antibody-drug conjugate’s global market withdrawal in 2022. | GSK has secured the first regulatory approval for Blenrep since the ...